Table of Content
Chapter 1 Research Methodology
1.1 Research Methodology
1.2 Geographic Scope & Assumptions
1.3 Years Considered
1.4 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Introduction
3.1 Key Findings
3.2 Value Chain Analysis
3.2.1 Upstream
3.2.2 Downstream
Chapter 4 Manufacture
4.1 Manufacturing Process
4.2 Issues and Trends
Chapter 5 Cost Structure
5.1 Bill of Material
5.2 Manufacturing Cost
5.3 Labor Cost
5.4 Depreciation Cost
Chapter 6 Worldwide Key Vendors
6.1 Profile
6.1.1 GlaxoSmithKline (GSK) Plc
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Alchemia Ltd.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Apotex, Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 Dr Reddy's Laboratories Ltd.
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Product Benchmarking
6.1.4.4 Strategic Initiatives
6.1.5 ScinoPharm Taiwan., Ltd.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Product Benchmarking
6.1.5.4 Strategic Initiatives
6.1.6 Lupin Pharmaceuticals, Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Product Benchmarking
6.1.6.4 Strategic Initiatives
6.1.7 Abbott Laboratories, Inc.
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Product Benchmarking
6.1.7.4 Strategic Initiatives
6.2 Market Share Trends
Chapter 7 Market Status
7.1 Market Size, 2015
7.1.1 Global Fondaparinux market, 2011 - 2024 (USD million)
7.2 Market Volume, 2015
7.2.1 Global Fondaparinux market, volume, 2011 - 2024 (Thousand Units)
7.3 Competitive Landscape
7.3.1 Heat Map
Chapter 8 Market Overview (Variables, Trends & Scope)
8.1 Market Segmentation & Scope
8.2 Global Production Volume, 2011 - 2016
8.2.1 Global Fondaparinux market, volume, 2011 - 2016 (thousand units)
8.3 Production Volume by Region, 2011 - 2016
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 China
8.3.5 RoW
8.4 Global Production Value, 2011 - 2016
8.4.1 Global Fondaparinux market, 2011 - 2016 (USD million)
8.5 Production Value by Region, 2011 - 2016
8.5.1 North America
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 China
8.5.5 RoW
Chapter 9 Market Forecast
9.1 Regional Market Size Forecast, 2016 to 2024
9.1.1 North America
9.1.2 Europe
9.1.3 Asia Pacific
9.1.4 China
9.1.5 RoW
9.2 Regional Consumption Forecast, 2016 - 2024
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 China
9.2.5 RoW
Chapter 10 Market Dynamics
10.1 Market Drivers
10.1.1 Expanding applications of Fondaparinux in various therapeutic areas
10.1.2 Expanding target audience in the Fondaparinux market
10.1.3 Introduction of generics in the market
10.2 Market Constraints
10.2.1 High setup cost
10.3 Market Opportunities
Chapter 11 Investment Feasibility
11.1 Global Economic Highlight 2015
11.2 Recent Developments
11.3 The Updated Forecast
11.3.1 Advanced Economies
11.3.2 Emerging Markets and Developing Economies
11.4 China Outlook
11.5 Investment in China
11.5.1 Outlook on investment
11.5.2 Growth opportunities
11.5.3 Policy trends
11.5.4 Conclusions
11.6 Feasibility of New Project
11.6.1 Basis and presumptions
11.6.2 New project
List of Tables
TABLE 1 Death rates and severe bleeding: Fondaparinux versus low molecular weight heparin
List of Figures
FIG. 1 Fondaparinux upstream value chain analysis
FIG. 2 Fondaparinux downstream value chain analysis
FIG. 3 Breakdown of materials & inputs by price (%)
FIG. 4 Breakdown of manufacturing cost (%)
FIG. 5 Fondaparinux market company market share, 2014
FIG. 6 Market summary, 2015 (USD million)
FIG. 7 Global Fondaparinux market, by revenue, 2011 - 2024 (USD million)
FIG. 8 Global Fondaparinux market, volume, 2011 - 2024 (Thousand Units)
FIG. 9 Fondaparinux Market: Heat Map Analysis, 2014
FIG. 10 Market trends & outlook
FIG. 11 Market segmentation & scope
FIG. 12 Global Fondaparinux market, volume, 2011 - 2016 (thousand units)
FIG. 13 North America Fondaparinux market, volume, 2011 - 2016 (thousand units)
FIG. 14 Europe Fondaparinux market, volume, 2011 - 2016 (thousand units)
FIG. 15 Asia Pacific Fondaparinux market, volume, 2011 - 2016 (thousand units)
FIG. 16 China Fondaparinux market, volume, 2011 - 2016 (thousand units)
FIG. 17 RoW Fondaparinux market, by volume, 2011 - 2016 (thousand units)
FIG. 18 Global Fondaparinux market, revenue, 2011 - 2016 (USD million)
FIG. 19 North America Fondaparinux market, revenue, 2011 - 2016 (USD million)
FIG. 20 Europe Fondaparinux market, revenue, 2011 - 2016 (USD million)
FIG. 21 Asia Pacific Fondaparinux market, revenue, 2011 - 2016 (USD million)
FIG. 22 China Fondaparinux market, revenue, 2011 - 2016 (USD million)
FIG. 23 RoW Fondaparinux market, revenue, 2011 - 2016 (USD million)
FIG. 24 North America Fondaparinux market, revenue, 2016 - 2024 (USD million)
FIG. 25 Europe Fondaparinux market, revenue, 2016 - 2024 (USD million)
FIG. 26 Asia Pacific Fondaparinux market, revenue, 2016 - 2024 (USD million)
FIG. 27 China Fondaparinux market, revenue, 2016 - 2024 (USD million)
FIG. 28 RoW Fondaparinux market, revenue, 2016 - 2024 (USD million)
FIG. 29 North America Fondaparinux market, volume, 2016 - 2024 (Thousand Units)
FIG. 30 Europe Fondaparinux market, volume, 2016 - 2024 (Thousand Units)
FIG. 31 Asia Pacific Fondaparinux market, volume, 2016 - 2024 (Thousand Units)
FIG. 32 China Fondaparinux market, volume, 2016 - 2024 (Thousand Units)
FIG. 33 RoW Fondaparinux market, volume, 2016 - 2024 (Thousand Units)
FIG. 34 Population 65+ by age:1900 - 2020
FIG. 35 Key Opportunities Prioritized, 2014
FIG. 36 Healthcare expenditure (% of GDP), 2008 - 2014 (USD million)
FIG. 37 Fondaparinux market, 2011 - 2024 (USD million)
FIG. 38 China: Pharmaceutical industry 2015